NCT00980694

Bioavailability of Ubiquinol in Huntington Disease

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: University of Rochester · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The death of brain cells in Huntington Disease (HD) is thought to be associated with a lack of normal cell energy and harmful brain substances called free radicals. Coenzyme Q10 (CoQ) is a marketed nutritional supplement that may prove useful in HD because it increases cell energy and combats free radicals. Most studies of CoQ have looked at only one formulation of CoQ ("ubiquinone") in HD. The purpose of the study is to find out if people that switch from the common formulation of CoQ ("ubiquinone") to a different formulation ("ubiquinol") have higher levels of CoQ in their blood after taking the same dose. The investigators also want to find out if this different formulation is tolerable for individuals with HD.

Conditions

• Huntington Disease

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	ubiquinol	up to 600 mg per day, oral capsules for 8 weeks

Timeline

• Start date: 2009-09-01
• Primary completion: 2012-07-01
• Completion: 2012-07-01
• First posted: 2009-09-21
• Last updated: 2016-05-27

Locations

1 site across 1 country: United States